Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG2a|
|Immunogen||Recombinant protein encoding the external domain of human CD14|
|Storage buffer||tissue culture supernatant|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||1:2|
|Immunohistochemistry (Paraffin) (IHC (P))||1:20-1:40|
|Western Blot (WB)||1:10-1:100|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunohistochemistry (IHC)||See 2 publications below|
MA5-11394 targets CD14 in IHC (P), FACS and WB applications and shows reactivity with Human samples.
The MA5-11394 immunogen is recombinant protein encoding the external domain of human CD14.
CD14 (also known lipopolysaccharide (LPS) receptor) is expressed strongly on monocytes and macrophage and weakly on the surface of neutrophils. CD14 is anchored to cells by linkage to glycosylphosphatidylinositol (GPI) and functions as a high affinity receptor for complexes of LPS and LPS binding protein (LBP). Soluble CD14, also binding to LPS, acts at physiological concentration as an LPS agonist and has, at higher concentrations, an LPS antagonizing effect in cell activation.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
The novel immunosuppressive enzyme IL4I1 is expressed by neoplastic cells of several B-cell lymphomas and by tumor-associated macrophages.
MA5-11394 was used in immunohistochemistry to investigate the expression of IL4I1 in neoplastic cells and tumor-associated macrophages
|Carbonnelle-Puscian A,Copie-Bergman C,Baia M,Martin-Garcia N,Allory Y,Haioun C,Cr?mades A,Abd-Alsamad I,Farcet JP,Gaulard P,Castellano F,Molinier-Frenkel V||Leukemia (23:952)||2009|
Combined therapy of transcatheter hepatic arterial embolization with intratumoral dendritic cell infusion for hepatocellular carcinoma: clinical safety.
MA5-11394 was used in immunohistochemistry to study the use of transcatheter hepatic arterial embolization with intratumoral dendritic cell infusion for hepatocellular carcinoma
|Nakamoto Y,Mizukoshi E,Tsuji H,Sakai Y,Kitahara M,Arai K,Yamashita T,Yokoyama K,Mukaida N,Matsushima K,Matsui O,Kaneko S||Clinical and experimental immunology (147:296)||2007|
monocyte differentiation antigen CD14; myeloid cell-specific leucine-rich glycoprotein